WuHan Pharmstar Pharmaceutical Co., Ltd.

Primary objective: To compare the differences in the extent and rate of absorption of loxoprofen sodium gel patch (test preparation T, specification: each patch contains 100 mg of loxoprofen sodium (calculated as C15H17NaO3) (area 14.0 cm×10.0 cm, paste content 10 g)) produced by Wuhan Farmaxing Pharmaceutical Co., Ltd. and loxoprofen sodium gel patch (reference preparation R, trade name: LOXONIN ®, specification: each patch contains 100 mg of loxoprofen sodium (calculated as C15H17NaO3) (area 14.0 cm×10.0 cm, paste content 10 g)) produced by LEAD CHEMICAL CO., LTD in healthy subjects under single application conditions. The statistical analysis of the main pharmacokinetic parameters was used to evaluate whether the two products were bioequivalent. Secondary objective: To evaluate the safety, adhesion firmness and skin reactivity of loxoprofen sodium gel patch by observing the safety indicators and adhesion firmness and skin reactivity scores at different time points after single application of the test preparation and reference preparation in healthy subjects.

Primary objective: To compare the differences in absorption extent and speed of flurbiprofen gel patch (test preparation T, specification: 40 mg/patch, 13.6×10 cm2, paste content 12 g) produced by Wuhan Farma Star Pharmaceutical Co., Ltd. and flurbiprofen gel patch (reference preparation R, trade name: Zepus®, specification: 40 mg/patch, 13.6×10 cm2, paste content 12 g) produced by Mikasa Seiyaku Co., Ltd under single application conditions in healthy subjects. Statistical analysis of the main pharmacokinetic parameters was used to evaluate whether the two were bioequivalent. Secondary objective: To evaluate the safety, adhesion firmness and skin irritation of flurbiprofen gel patch by observing the safety indicators and adhesion firmness and skin irritation scores at different time points after single application of the test preparation and reference preparation in healthy subjects.

Primary objective: To evaluate the bioequivalence of single-application drug between the test preparation and the reference preparation in healthy adult volunteers by comparing the flurbiprofen gel patch (test preparation T 40mg/patch (13.6cm×10cm) containing 12g of paste) produced by Wuhan Farmaxing Pharmaceutical Co., Ltd. with Zepus® (reference preparation R, generic name: flurbiprofen gel patch, 40mg/patch (13.6cm×10cm, containing 12g of paste) produced by Mikasa Pharmaceutical Co., Ltd., according to the relevant provisions of the bioequivalence test. Secondary objective: To evaluate the safety, skin reactivity and adhesion of the single-application test preparation (flurbiprofen gel patch T) and the reference preparation (Zeps® R) in healthy adult subjects in China.